Endo CEO Reveals Glimpse Of New Strategy: Highlights Generics Potential
This article was originally published in The Pink Sheet Daily
During Endo’s first quarter sales and earnings call, new CEO Rajiv De Silva said his strategic review of the specialty pharma is still underway but offered investors some initial thoughts on his plans for the company.
You may also be interested in...
Formerly of Valeant, new CEO Rajiv De Silva appears to be reworking Endo in the mold of his previous company, with plans to divest its early-stage pipeline and focus on growth through business development.
FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.
By buying the sixth-largest generics firm in the U.S. Endo gets what it says is critical mass in the U.S. generics market and significant domestic manufacturing capability.